Literature DB >> 20412507

Beyond gastrointestinal graft-versus-host disease. A lesson to learn.

Adam Gassas1, Irina Zaidman, Tal Schechter, John Doyle.   

Abstract

The authors present a child with severe GvHD of GI tract with typical presentation of ileus and abdominal pain. However, the severe GvHD has led to multiple intermittent intussusceptions with resultant ischemic segments of the small bowel leading to sub-acute mechanical intestinal obstruction. The clinical presentation of the mechanical intestinal obstruction was identical to the preceding ileus GvHD presentation. This has led to continuation of the conservative management with immunosuppressant therapy and delaying further investigation and surgical intervention. Once a barium study demonstrated the severe bowel constriction, laparoscopic surgical resection was necessary with excellent results. The resected small bowel showed multiple segments of ischemic ileitis leading to ulceration and severe stricture. The resection margins showed regenerating mucosa with no ulceration, but with focal evidence of mild GvHD.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412507     DOI: 10.1111/j.1399-3046.2010.01327.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Colonic perforation in graft versus host disease: a case report.

Authors:  Nandini C Palaniappa; Laura Doyon; Celia M Divino
Journal:  Int Surg       Date:  2012 Jan-Mar

2.  Superselective arterial embolization of the superior mesenteric artery for the treatment of gastrointestinal hemorrhage following allogeneic hematopoietic stem cell transplantation.

Authors:  Run-Zhe Chen; Gang Zhao; Nan Jin; Bao-An Chen; Jia-Hua Ding
Journal:  Patient Prefer Adherence       Date:  2014-11-13       Impact factor: 2.711

3.  Graft-versus-host disease complicated with small bowel obstruction in children: A case report.

Authors:  Yizhong Wang; Jiangbin Liu; Bingxin Jiang; Chenling Yuan; Licai Chen; Ting Zhang; Zhibao Lv
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.